Third Biennial Symposium on Biology, Diagnosis and Treatment of Lymphomas
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: August 15, 2005
Conference Dates: Friday, October 14, 2005 Conference Location: Marriott West, West Conshohocken, PA
Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania
Conference Brochure:Download PDF version of conference brochure.
Topics Covered: Non-Hodgkins, Hodgkins, Prognostic Markers, New Targeted Therapies
Conference Objectives: At the completion of this conference, participants should be able to:
Discuss the current classification of lymphomas as well as the controversies in diagnosis and their impact on management;
Gain new insight into pathogenesis of lymphomas;
Appreciate the growing role of understanding the basic mechanisms of the disease in diagnosis and treatment of lymphomas;
Critically assess novel diagnostic and therapeutic approaches to lymphomas
Who Should Attend: Clinical Oncologists, Pathologists, Hematopathologists, Oncology Nurses and other health care professional involved in the treatment of patients with lymphoma
Welcome and Introduction: John Glick
Classification of lymphomas: Dale Frank
Biology of non-Hodgkin’s lymphomas: diagnostic and therapeutic implications: Mariusz A. Wasik
Biology of Hodgkin lymphoma: Harald Stein (Free Univ. Berlin) 9:40- 9:55 Questions and Answers
Proteomic analysis of aberrant cell signaling in lymphomas: Kojo Elenitoba-Johnson (Univ. of Utah)
Prognostic markers in small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL): Adam Bagg
siRNA expression profile of SLL/CLL: Carlo Croce (Ohio State)
Glucose metabolism by lymphoma cells: diagnostic and therapeutic implications: Rebecca Ellstrom (Univ. of Michigan)
Antibody-based therapy of lymphomas: John Leonard (Weill/Cornell)
Histone deactehylase inhibitors in treatment of lymphomas: Ellen Kim
Targeted therapies for SLL/CLL: John Byrd (Ohio State)
Targeted therapies for non SLL/CLL small B-cell lymphomas: Stephen Schuster
New therapeutic agents for aggressive B-cell lymphoma: Sunita Nasta
Closing remarks: Mariusz Wasik/Stephen Schuster
Registration Information: For more information, or to request a brochure, please contact Mary Graham at 215-662-7328 or email@example.com.
Conference Fees: $175.00 physician, $95.00 nurses and other health care professionals, No fee for faculty, staff, fellows & students of the University of Pennsylvania
Online Registration All fields are required.
Make checks payable to: Trustees, University of Pennsylvania. Mail payment and registration to:
Abramson Cancer Center of the University of Pennsylvania
3400 Spruce St. - 16 Penn Tower
Philadelphia, PA 19104-4283
P: 215-662-7328 • F: 215-614-1854
Continuing Education: Yes. The University of Pennsylvania School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Jun 18, 2012 - Approximately one-third of patients with natural killer/T-cell lymphoma (NKTCL) harbor somatic-activating Janus kinase 3 (JAK3) mutations, according to a study published online June 15 in Cancer Discovery.